MRKR News and Press, Marker Therapeutics Inc. From 11/09/23

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Marker Therapeutics Inc. (MRKR) is expected to report for Q1 2024

2023-09-11 08:20:32 ET More on Marker Financial information for Marker Therapeutics For further details see: Marker gains as lymphoma therapy leads to complete remission

Marker Therapeutics reports clinical updates in APOLLO trial for the treatment of lymphoma patients who have relapsed after anti-CD19 CAR T cell therapy Patient with Non-Hodgkin’s Lymphoma who relapsed after anti-CD19 CAR T cell therapy tolerated initial dose level well and achie...

HOUSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan ...

Cranford, New Jersey--(Newsfile Corp. - August 17, 2023) - Marker Therapeutics (NASDAQ: MRKR) highlights its technology during a recently held, 75-minute Demi-Colton Virtual Salon/Webinar on cell therapy and CAR-T, a breakthrough cancer treatment that modifies a patient's own T cells to fight can...

2023-08-14 17:41:57 ET Marker Therapeutics press release ( NASDAQ: MRKR ): Q2 GAAP EPS of -$0.47. Revenue of $0.76M (-3.8% Y/Y). Shares +3.43% AH. For further details see: Marker Therapeutics GAAP EPS of -$0.47, revenue of $0.76M

Executed comprehensive non-dilutive agreement with Cell Ready TM , resulting in an extended financial runway into the fourth quarter of 2025 Appointed Juan Vera, M.D. as President and Chief Executive Officer and Monic Stuart, M.D., MPH, as Chief Medical Officer to spearhead ...

HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced non-clinic...

2023-07-31 13:08:57 ET Gainers: Mallinckrodt ( MNK ) +42% . Fifth Wall Acquisition Corp. III ( FWAC ) +40% . Tupperware Brands Corporation ( TUP ) +40% . GoodRx Holdings ( GDRX ) +37% . Archer Aviation ( ACHR ) +36% . Steakho...